Nuclera

Executive Summary

Nuclera is a UK-based biotechnology company founded in 2013 that specializes in rapid protein prototyping. The company's core technology is an end-to-end multiplex protein screening system that accelerates the design, screening, and production of assay-ready proteins, including challenging membrane proteins, within days. By streamlining the traditionally slow and costly process of protein production, Nuclera aims to make proteins accessible for drug discovery and synthetic biology applications. The platform addresses a critical bottleneck in the development of biologics, enabling researchers to evaluate multiple protein variants simultaneously and accelerate target validation. With its innovative approach, Nuclera is poised to disrupt the protein engineering market, which is increasingly important for the development of next-generation therapeutics. The company operates from Cambridge, UK, and has garnered attention for its potential to significantly reduce the time and cost associated with protein research.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of the eProtein Discovery system80% success
• H2 2026Strategic partnership with a top-20 pharmaceutical company60% success
• Q3 2026Series B funding round closure75% success